Janux Therapeutics (NASDAQ:JANX) Stock Price Down 3.3%

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) fell 3.3% during mid-day trading on Wednesday . The company traded as low as $37.50 and last traded at $37.55. 35,011 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 717,234 shares. The stock had previously closed at $38.84.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. BTIG Research assumed coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They set a “buy” rating and a $62.00 target price for the company. Cantor Fitzgerald began coverage on Janux Therapeutics in a research note on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Wedbush reiterated an “outperform” rating and issued a $53.00 price objective on shares of Janux Therapeutics in a report on Monday, March 11th. Finally, Bank of America upped their price target on Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, March 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $59.60.

Janux Therapeutics Stock Down 0.7 %

The company’s fifty day simple moving average is $24.28 and its 200 day simple moving average is $14.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its position in shares of Janux Therapeutics by 10,740.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock valued at $29,000 after buying an additional 2,685 shares during the period. Tower Research Capital LLC TRC raised its stake in Janux Therapeutics by 149.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock valued at $40,000 after buying an additional 2,003 shares during the last quarter. Barclays PLC lifted its holdings in Janux Therapeutics by 533.0% in the fourth quarter. Barclays PLC now owns 4,608 shares of the company’s stock valued at $61,000 after acquiring an additional 3,880 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Janux Therapeutics in the fourth quarter worth approximately $57,000. Finally, Citigroup Inc. boosted its stake in shares of Janux Therapeutics by 935.2% during the 2nd quarter. Citigroup Inc. now owns 5,787 shares of the company’s stock worth $69,000 after acquiring an additional 5,228 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.